Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Toxoplasmosis, Congenital | 5 | 2015 | 8 | 0.650 |
Why?
|
| Toxoplasma | 4 | 2017 | 8 | 0.460 |
Why?
|
| Muscular Dystrophy, Duchenne | 3 | 2022 | 6 | 0.460 |
Why?
|
| Toxoplasmosis | 2 | 2017 | 6 | 0.270 |
Why?
|
| Toxoplasmosis, Ocular | 1 | 2006 | 2 | 0.270 |
Why?
|
| Vision Disorders | 1 | 2006 | 20 | 0.270 |
Why?
|
| Leukodystrophy, Globoid Cell | 1 | 2005 | 1 | 0.250 |
Why?
|
| Encephalomyelitis, Acute Disseminated | 1 | 2005 | 3 | 0.250 |
Why?
|
| Antibodies, Protozoan | 4 | 2017 | 5 | 0.220 |
Why?
|
| Morpholinos | 1 | 2022 | 3 | 0.200 |
Why?
|
| Mobility Limitation | 1 | 2022 | 90 | 0.180 |
Why?
|
| Immunoglobulin G | 3 | 2017 | 92 | 0.180 |
Why?
|
| Registries | 1 | 2022 | 170 | 0.180 |
Why?
|
| Immunoglobulin M | 2 | 2017 | 16 | 0.170 |
Why?
|
| Child, Preschool | 5 | 2015 | 652 | 0.170 |
Why?
|
| Cognition Disorders | 1 | 2006 | 970 | 0.160 |
Why?
|
| Immunoassay | 2 | 2017 | 38 | 0.160 |
Why?
|
| Disease Progression | 1 | 2022 | 676 | 0.160 |
Why?
|
| Codon, Nonsense | 1 | 2017 | 3 | 0.140 |
Why?
|
| Oxadiazoles | 1 | 2017 | 8 | 0.140 |
Why?
|
| Infant, Newborn | 5 | 2015 | 563 | 0.140 |
Why?
|
| Point-of-Care Testing | 1 | 2017 | 29 | 0.140 |
Why?
|
| Infant | 5 | 2015 | 541 | 0.130 |
Why?
|
| Hydrocephalus | 1 | 2015 | 19 | 0.130 |
Why?
|
| Child | 5 | 2022 | 1326 | 0.120 |
Why?
|
| Family Health | 1 | 2015 | 33 | 0.120 |
Why?
|
| Cluster Analysis | 1 | 2015 | 45 | 0.120 |
Why?
|
| Fathers | 1 | 2015 | 22 | 0.120 |
Why?
|
| Hypotension | 1 | 2015 | 28 | 0.120 |
Why?
|
| Genotype | 1 | 2015 | 350 | 0.110 |
Why?
|
| Adolescent | 5 | 2022 | 2172 | 0.110 |
Why?
|
| Heart Failure | 1 | 2015 | 148 | 0.110 |
Why?
|
| Food Contamination | 1 | 2011 | 3 | 0.100 |
Why?
|
| Humans | 12 | 2022 | 26260 | 0.100 |
Why?
|
| Eating | 1 | 2011 | 57 | 0.090 |
Why?
|
| Visual Acuity | 2 | 2006 | 38 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2022 | 1665 | 0.080 |
Why?
|
| Male | 7 | 2022 | 14168 | 0.080 |
Why?
|
| Female | 7 | 2015 | 14520 | 0.080 |
Why?
|
| Pregnancy | 3 | 2015 | 312 | 0.070 |
Why?
|
| Vision, Binocular | 1 | 2006 | 1 | 0.070 |
Why?
|
| Vision, Monocular | 1 | 2006 | 1 | 0.070 |
Why?
|
| Macula Lutea | 1 | 2006 | 2 | 0.070 |
Why?
|
| Wechsler Scales | 1 | 2006 | 9 | 0.070 |
Why?
|
| Intelligence Tests | 1 | 2006 | 14 | 0.070 |
Why?
|
| Pattern Recognition, Visual | 1 | 2006 | 17 | 0.070 |
Why?
|
| Language Tests | 1 | 2006 | 23 | 0.070 |
Why?
|
| Antiprotozoal Agents | 1 | 2006 | 8 | 0.070 |
Why?
|
| United States | 4 | 2017 | 2043 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 343 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 94 | 0.060 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 1 | 2002 | 1 | 0.050 |
Why?
|
| Thoracic Neoplasms | 1 | 2002 | 9 | 0.050 |
Why?
|
| Neuroblastoma | 1 | 2002 | 18 | 0.050 |
Why?
|
| Abdominal Neoplasms | 1 | 2002 | 13 | 0.050 |
Why?
|
| Prevalence | 2 | 2015 | 441 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2002 | 78 | 0.050 |
Why?
|
| Vital Capacity | 1 | 2022 | 10 | 0.050 |
Why?
|
| Walk Test | 1 | 2022 | 8 | 0.050 |
Why?
|
| Mass Screening | 1 | 2002 | 174 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2015 | 1801 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2022 | 3283 | 0.040 |
Why?
|
| Chicago | 2 | 2015 | 857 | 0.040 |
Why?
|
| Time Factors | 1 | 2022 | 1347 | 0.040 |
Why?
|
| Dystrophin | 1 | 2017 | 1 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 11 | 0.040 |
Why?
|
| Developing Countries | 1 | 2017 | 14 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 28 | 0.040 |
Why?
|
| Global Health | 1 | 2017 | 37 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2017 | 411 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 473 | 0.030 |
Why?
|
| Agglutination Tests | 1 | 2015 | 4 | 0.030 |
Why?
|
| Serogroup | 1 | 2015 | 2 | 0.030 |
Why?
|
| Systole | 1 | 2015 | 16 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 2015 | 34 | 0.030 |
Why?
|
| Walking | 1 | 2017 | 249 | 0.030 |
Why?
|
| Echocardiography | 1 | 2015 | 92 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2015 | 197 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2017 | 3285 | 0.030 |
Why?
|
| Incidence | 1 | 2015 | 709 | 0.030 |
Why?
|
| Serotyping | 1 | 2012 | 10 | 0.020 |
Why?
|
| Virulence | 1 | 2012 | 10 | 0.020 |
Why?
|
| Oocysts | 1 | 2011 | 2 | 0.020 |
Why?
|
| North America | 1 | 2011 | 32 | 0.020 |
Why?
|
| Alleles | 1 | 2012 | 206 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2011 | 25 | 0.020 |
Why?
|
| Adult | 2 | 2015 | 7516 | 0.020 |
Why?
|
| Young Adult | 1 | 2015 | 1948 | 0.020 |
Why?
|
| Pyrimethamine | 1 | 2006 | 2 | 0.020 |
Why?
|
| Sulfadiazine | 1 | 2006 | 2 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 154 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2006 | 199 | 0.020 |
Why?
|
| Serologic Tests | 1 | 2002 | 9 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2002 | 77 | 0.010 |
Why?
|
| Age of Onset | 1 | 2002 | 94 | 0.010 |
Why?
|
| Ataxia | 1 | 2002 | 74 | 0.010 |
Why?
|
| Recurrence | 1 | 2002 | 288 | 0.010 |
Why?
|
| Comorbidity | 1 | 2002 | 468 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2002 | 875 | 0.010 |
Why?
|
| Cognition | 1 | 2006 | 1276 | 0.010 |
Why?
|